Endocrine Abstracts

Introduction: NETs are regarded as rare endocrine malignancies, which often present late. The COVID-19 pandemic may have affected this and patient care. The impact will have been felt in health service delivery and patient experiences. To understand NET patient perspectives and optimise care, we conducted a survey to review patient perception of: telemedicine-based care, delays to imaging, treatment, and the impact of COVID-19.Method: 70 NET patients tre...

Introduction: In patients with neuroendocrine tumours (NETs) somatostatin analogues are used to control symptoms in patients with functioning tumours and as antiproliferative agents in those with non-functioning tumours. During COVID-19, the ‘Sandostatin Your Choice’ service was terminated by Novartis, removing home care nurses from administering the analogue in patients’ homes. The first generic version of depot octreotide was Olatuton® produced by Teva, a...